

**Amendments to the claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of claims:**

Claims 1-7 (cancelled).

8. (previously presented): A polymorph form 1 of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine hemifumarate having by the following x-ray powder diffraction pattern expressed in terms of "d" spacing and relative intensity (" $I/I_0$ "):

d	I/I <sub>0</sub>
12.32	26
10.53	11
8.444	19
8.149	16
6.550	25
6.281	22
6.185	35
6.084	19
5.553	88
5.373	64
5.096	59
4.960	41
4.745	34
4.470	26
4.403	30
4.365	46
4.159	84
4.124	73
4.061	35
3.750	79
3.716	100
3.659	27
3.589	14
3.398	11
3.362	16
3.277	10
3.090	23
3.051	11
3.003	15
2.784	10
2.507	12

9. (previously presented): A polymorph form 2 of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine hemifumarate having by the following x-ray powder diffraction pattern expressed in terms of "d" spacing and relative intensity ("I/I<sub>0</sub>"):

---

D	I/I <sub>0</sub>
14.14	14
10.74	13
7.158	39
7.084	20
5.983	12
5.663	61
5.365	33
5.267	100
5.064	12
4.973	46
4.809	16
4.745	43
4.477	32
4.449	26
4.399	60
4.317	54
4.012	49
3.772	26
3.745	61
3.722	97
3.590	88
3.561	59
3.385	24
2.986	17
2.949	11
2.836	20
2.778	10
2.616	10
2.481	12

---

10. (cancelled).

11. (previously presented): A solid pharmaceutical composition comprising an anti-allergic effective amount of the polymorph form 1 according to Claim 8 and a pharmaceutically acceptable carrier.

12. (previously presented): A solid pharmaceutical composition comprising an anti-allergic effective amount of the polymorph form 2 according to Claim 9 and a pharmaceutically acceptable carrier.

13. (cancelled).

14. (previously presented): A method of treating allergic reactions in a mammal which comprises administering to said mammal an anti-allergic effective amount of the polymorph form 1 according to Claim 8.

15. (previously presented): A method of treating allergic reactions in a mammal which comprises administering to said mammal an anti-allergic effective amount of the polymorph form 2 according to Claim 9.

16. (currently amended): A process for preparing polymorph form 1 of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine hemifumarate according to Claim 8 comprising:

(i) mixing desloratadine, fumaric acid, and ethanol at a temperature of from about 15°C to about 25°C to form a solid; and

(ii) filtering the solid to form the polymorphic form 1 of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine hemifumarate which is characterized by a DSC of  $224^{\circ}\text{C} \pm 2^{\circ}\text{C}$ .

17. (currently amended): A process for preparing polymorph form 1 of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine hemifumarate according to Claim 8 comprising:

(a) dissolving desloratadine in ethanol to form an ethanolic solution of desloratidine;

(b) dissolving fumaric acid in ethanol to form an ethanolic solution of fumaric acid;

(c) mixing the ethanolic solution of desloratidine and the ethanolic solution of fumaric acid at a temperature of from about 15°C to about 25°C to form a solid; and

(d) filtering the solid to form the polymorphic form 1 of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine hemifumarate which is characterized by a DSC of  $224^{\circ}\text{C} \pm 2^{\circ}\text{C}$ .

18. (previously presented): The process according to Claim 17 wherein the mixing in Step (c) is conducted for a period of time from about 30 to about 45 minutes.

19. (currently amended): A process for preparing polymorph form 2 of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine hemifumarate according to Claim 9 comprising:

(i)' mixing desloratadine, fumaric acid, and ethanol at a temperature of from about 55°C to about 70°C to form a solid; and

(ii)' filtering the solid to form the polymorphic form 2 of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine hemifumarate which is characterized by a DSC of  $232^{\circ}\text{C} \pm 2^{\circ}\text{C}$ .

20. (currently amended): A process for preparing polymorph form 2 of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine hemifumarate according to Claim 9 comprising:

(a)' dissolving desloratadine in ethanol to form an ethanolic solution of desloratidine;

(b)' dissolving fumaric acid in ethanol to form an ethanolic solution of fumaric acid;

(c)' mixing the ethanolic solution of desloratidine and the ethanolic solution of fumaric acid at a temperature of from about 55°C to about 70°C to form a solid; and

(d)' filtering the solid to form the polymorphic form 2 of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine hemifumarate which is characterized by a DSC of  $232^{\circ}\text{C} \pm 2^{\circ}\text{C}$ .

21. (previously presented): The process according to Claim 20 wherein the mixing in Step (c)' is conducted for a period of time from about 30 to about 45 minutes.